DNMT3A and cyclic hematopoiesis: Again, the distribution was similar to the patients with CH-related mutations, with DNMT3A being most frequent (six patients (46.2%)) followed by TET2 (five patients (38.5%)) and ASXL1 mutations (two patients (15.4%)).